MERCK & CO. INC.(NYSE:MRK) stock News

MRK Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

Merck & Co. Inc. (NYSE:MRK): A Prime Candidate for a Dependable Dividend Portfolio

12 days ago - By: Chartmill

Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances

19 hours ago - By: Stocktwits - Mentions: LLY

Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies

20 hours ago - By: Benzinga - Mentions: ABBV AMGN BIIB VRTX ...

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet

a day ago - By: The Motley Fool - Mentions: BBAI DBD SNY NVDA ...

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now

a day ago - By: Benzinga - Mentions: DVAX NVAX GSK PFE ...

Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'

a day ago - By: Stocktwits - Mentions: LLY AZN BIIB NVO ...

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

2 days ago - By: Stocktwits - Mentions: EVAX

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened

3 days ago - By: The Motley Fool - Mentions: PFE BMY

The Smartest Dividend Stock to Buy With $1,000 Right Now

5 days ago - By: Investor's Business Daily

Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff

7 days ago - By: Merck & Co., Inc.

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

7 days ago - By: Bloomberg

Merck Wins US Approval of Easier-to-Use Version of Cancer Drug Keytruda

8 days ago - By: Stocktwits - Mentions: DUHP VFMF

Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda

8 days ago - By: Merck & Co., Inc.

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season

8 days ago - By: Merck & Co., Inc.

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

9 days ago - By: Bloomberg

RFK Jr.’s Vaccine Panel Questions Use of Routine Childhood Shots

12 days ago - By: Daiichi Sankyo

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

14 days ago - By: Chartmill

Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen

15 days ago - By: Bloomberg

MERCK & CO. INC. (MRK) Stock News